<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00972257</url>
  </required_header>
  <id_info>
    <org_study_id>A5132</org_study_id>
    <nct_id>NCT00972257</nct_id>
  </id_info>
  <brief_title>24-hr Intraocular Pressure Control With Dorzolamide/Timolol vs the Brimonidine/Timolol Fixed Combination</brief_title>
  <official_title>Quality of 24-hour Intraocular Pressure Control Obtained With Dorzolamide/Timolol Fixed Combination (DTFC) Compared With the Brimonidine/Timolol Fixed Combination (BTFC) in Subjects With Primary Open-angle Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aristotle University Of Thessaloniki</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aristotle University Of Thessaloniki</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study will compare for the first time the quality of 24-hour IOP control with
      Brimonidine/Timolol fixed combination (BTFC) versus Dorzolamide/Timolol fixed combination
      (DTFC) after a run-in period of 2 months with timolol. This crossover comparison may
      determine the real efficacy of the two fixed combinations and the design of the proposed
      study may explain for the first time why the 24-hour IOP reduction provided by BTFC is less
      than might be anticipated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the quality of 24-hour IOP control after 2 months of chronic therapy with the Dorzolamide/Timolol fixed combination versus the Brimonidine/Timolol fixed combination in primary open-angle glaucoma.</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess fluctuation of 24-hour pressure</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Drug: Dorzolamide/Timolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment with Brimonidine/Timolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>treatment with dorzolamide/timolol</intervention_name>
    <description>24-hour IOP control with the two fixed combinations</description>
    <arm_group_label>Drug: Dorzolamide/Timolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>treatment with brimonidine/timolol</intervention_name>
    <description>24-hour pressure control with brimonidine/timolol</description>
    <arm_group_label>Treatment with Brimonidine/Timolol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Consecutive, newly diagnosed or previously untreated POAG patients

          -  Patients with typical glaucomatous disc, or visual field damage

          -  Patient must have IOP (at 10:00 ± 1 hour)greater than 25 mm Hg

        Exclusion Criteria:

          -  Uncontrolled glaucoma

          -  Distance best corrected Snellen visual acuity worse than 1/10

          -  Contraindications to brimonidine or dorzolamide and β-blockers

          -  History of lack of response (&lt;10% morning IOP reduction) to any medication

          -  Patient can not understand the instructions and adhere to medications

          -  Patient is a female of childbearing potential or lactating mother

          -  Prior surgery, past use of steroids (within 2 months)

          -  Severe dry eyes and use of contact lenses

          -  History of non-adherence

          -  Patients with closed angles
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>29 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anastasios Konstas, MD, phD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head of Glaucoma Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Glaucoma Unit, 1st University Dept of Ophthalmology</name>
      <address>
        <city>Thessaloniki</city>
        <zip>546 36</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2009</study_first_submitted>
  <study_first_submitted_qc>September 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2009</study_first_posted>
  <last_update_submitted>May 9, 2014</last_update_submitted>
  <last_update_submitted_qc>May 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aristotle University Of Thessaloniki</investigator_affiliation>
    <investigator_full_name>AGP Konstas</investigator_full_name>
    <investigator_title>Professor in Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>24-hour IOP control</keyword>
  <keyword>primary open-angle glaucoma</keyword>
  <keyword>brimonidine/timolol</keyword>
  <keyword>dorzolamide/timolol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Dorzolamide</mesh_term>
    <mesh_term>Brimonidine Tartrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

